SER-401
Metastatic melanoma (in combination with nivolumab)
Phase 1bCompleted
Key Facts
Indication
Metastatic melanoma (in combination with nivolumab)
Phase
Phase 1b
Status
Completed
Company
About Seres Therapeutics
Seres Therapeutics is a clinical-stage microbiome therapeutics company focused on revolutionizing patient care by harnessing the power of the human microbiome. The company achieved a landmark milestone with the FDA approval of VOWST™, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infection. Seres continues to advance a diverse pipeline targeting significant unmet medical needs in infectious diseases, inflammatory bowel disease, and oncology through its proprietary microbiome platform and strategic collaborations.
View full company profile